Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Safety Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients with Advanced Emphysema
This study is currently recruiting patients.
Sponsored by: | Aeris Therapeutics |
---|---|
Information provided by: | Aeris Therapeutics |
Purpose
The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.
Condition | Treatment or Intervention | Phase |
---|---|---|
Pulmonary Emphysema |
Procedure: Aeris BLVR Treatment Drug: Aeris BLVR Treatment Device: Aeris BLVR Treatment |
Phase I |
MedlinePlus related topics: Emphysema
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: A Single-center, Non-blinded, Non-randomized, Non-controlled Phase 1 Trial Assessing the Safety of the Aeris Therapeutics Bronchoscopic Lung Volume Reduction (BLVR) System in Patients with Advanced Heterogeneous Emphysema
Expected Total Enrollment: 6
Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky.
Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Location and Contact Information
More Information
Publications
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |